Abstract:Huntington's disease is caused by a CAG repeat expansion in the Huntingtin gene (HTT), coding for polyglutamine in the Huntingtin protein, with longer CAG repeats causing earlier age of onset. The variable 'Age' × ('CAG'-L), where 'Age' is the current age of the individual, 'CAG' is the repeat length and L is a constant (reflecting an approximation of the threshold), termed the 'CAG Age Product' (CAP) enables the consideration of many individuals with different CAG repeat expansions at the same time for analysis of any variable and graphing using the CAG Age Product score as the X axis. Structural MRI studies have showed that progressive striatal atrophy begins many years prior to the onset of diagnosable motor Huntington's disease, confirmed by longitudinal multicentre studies on three continents, including PREDICT-HD, TRACK-HD and IMAGE-HD. However, previous studies have not clarified the relationship between striatal atrophy, atrophy of other basal ganglia structures, and atrophy of other brain regions. The present study has analysed all three longitudinal datasets together using a single image segmentation algorithm and combining data from a large number of subjects across a range of CAG Age Product score. In addition, we have used a strategy of normalizing regional atrophy to atrophy of the whole brain, in order to determine which regions may undergo preferential degeneration. This made possible the detailed characterization of regional brain atrophy in relation to CAG Age Product score. There is dramatic selective atrophy of regions involved in the basal ganglia circuit-caudate, putamen, nucleus accumbens, globus pallidus and substantia nigra. Most other regions of the brain appear to have slower but steady degeneration. These results support (but certainly do not prove) the hypothesis of circuit-based spread of pathology in Huntington's disease, possibly due to spread of mutant Htt protein, though other connection-based mechanisms are possible. Therapeutic targets related to prion-like spread of pathology or other mechanisms may be suggested. In addition, they have implications for current neurosurgical therapeutic approaches, since delivery of therapeutic agents solely to the caudate and putamen may miss other structures affected early, such as nucleus accumbens and output nuclei of the striatum, the substantia nigra and the globus pallidus.

Unraveling progression subtypes in people with Huntington's disease

Therapy development in Huntington disease: From current strategies to emerging opportunities

Huntington’s Disease: Relationship Between Phenotype and Genotype

Progress in studies of gene therapy for Huntington's disease

Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease

Advances in Gene and Cellular Therapeutic Approaches for Huntington’s Disease

Huntington disease: natural history, biomarkers and prospects for therapeutics

Pathomechanisms of behavioral abnormalities in Huntington disease: an update

Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease reveal shared and tissue-specific effects

Huntington's Disease: Latest Frontiers in Therapeutics

Modifiable factors associated with Huntington's disease progression in presymptomatic participants

Identification of genetic modifiers of Huntington's disease somatic CAG repeat instability by in vivo CRISPR-Cas9 genome editing

Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington's disease

Complex Pathogenesis and Therapeutic Strategies

Identifying and verifying Huntington's disease subtypes: Clinical features, neuroimaging, and cytokine changes

Identification of genetic modifiers of Huntington′s disease somatic CAG repeat instability by in vivo CRISPR-Cas9 genome editing

Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi-Targeted/Functional Drugs Based on Clinicaltrials.gov

Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics

Huntington's Disease: Understanding Its Novel Drugs and Treatments

Long somatic DNA-repeat expansion drives neurodegeneration in Huntington disease

Longitudinal imaging highlights preferential basal ganglia circuit atrophy in Huntington's disease